Contribute Try STAT+ Today

In response to a spate of pharmaceutical mergers, several antitrust regulators and enforcement agencies from the U.S. and Europe are forming a working group to better understand the impact these deals have on prescription drug pricing and competition.

The goal is to update the approach taken to analyzing potential economic harms that a merger may cause; the extent to which a merger may thwart R&D innovation; evidence needed to challenge a merger; and how other conduct in which companies have engaged — such as instances of pricing fixing — be considered when reviewing a deal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.